The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT

Molecular Endocrinology

Volumn 11, Issue 6, 1997, Pages 693-705

  Jackson, Twila A ^a   Richer, Jennifer K ^a   Bain, David L ^a   Takimoto, Glenn S ^a   Tung, Lin ^a   Horwitz, Kathryn B ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; ONAPRISTONE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ARTICLE; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 0030998328     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.11.6.0004     Document Type: Article

References (71)

1. Horwitz KB 1992 The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146-163
2. Jordan VC 1995 Studies on the estrogen receptor in breast cancer. Breast Cancer Res Treat 36:267-285
3. Nicholson RI, Francis AB, McClelland RA, Manning DL, Gee JMW 1994 Pure anti-oestrogens (ICI164384 and IC1182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile? Endocrine - Related Cancer 1:5-7
4. Fujimoto N, Katzenellenbogen BS 1994 Alterations in the agonist/antagonist balance of antiestrogens by activation of protein kinalse A signaling pathways in breast cancer cells: antiestrogens selectivity and promoter dependence. Mol Endocrinol 8:296-304
5. Meyer ME, Pomon A, Ji J, Bocquel M-T, Chambon P, Gronemeyer H 1990 Agonistic and antagonist activities of RU486 on the functions of the human progesterone receptor. EMBO J 9:3923-3932
6. Sartorius CA, Tung L, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 5:9262-9266
7. Horwitz KB 1995 Editorial: When tamoxifen turns bad. Endocrinology 136:821-823
8. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
10. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841-850
11. Tsai M-J, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
12. Sap J, Munoz J, Schmitt H, Stunnenberg H, Vennstrom B 1989 Repression of transcription mediated by a thyroid hormone response element by the v-Erb A oncogene product. Nature 340:242-244
13. Damm K, Thompson CC, Evans RM 1989 Protein encoded by v-Erb A functions as a thyroid hormone receptor antagonist. Nature 339:593-597
14. Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai M-J, O'Malley BW 1995 The t4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Mol Cell Biol 15:76-86
15. Smith DF, Toft DO 1993 Steroid receptors and their associated proteins. Mol Endocrinol 7:4-11
16. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L 1996 Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177
17. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-403
18. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451-454
19. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
20. Tong G-X, Jeyakumar M, Tanen MR, Bagchi MK 1996 Transcriptional silencing by unliganded thyroid hormone receptor β requires a soluble corepressor that interacts with the ligand-binding domain of the receptor. Mol Cell Biol 16:1909-1920
21. Seol W, Choi H-S, Moore DD 1995 Isolation of proteins that interact specifically with the retinoic X receptor: two novel orphan receptors. Mol Endocrinol 9:72-85
22. Lee JW, Choi H-S, Gyuris J, Brent R, Moore DD 1995 Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol 9:243-254
23. Bocquel M-T, Kumar V, Stricker C, Chambon P, Gronemeyer H 1989 The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell specific. Nucleic Acids Res 17:2581-2595
24. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131
25. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP 1993 The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 90:4441-4445
26. Sartorius CA, Groshong SD, Miller LA, Powell RP, Tung L, Takimoto GS, Horwitz KB 1994 New T47D breast cancer cell lines for the independent study of progester-one B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54:3868-3877
27. Fields S, Song OK 1989 A novel genetic system to detect protein-protein interactions. Nature 340:245-246
28. Chien C-T, Bartel PL, Sternglanz R, Fields S 1991 The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc Natl Acad Sci USA 88:9578-9582
29. Lin A, Chan Y-L, McNally J, Peleg D, Meyuhas O, Wool IG 1987 The primary structure of rat ribosomal protein L7. J Biol Chem 262:12665-12671
30. Tsurugi K, Collatz E, Wool IG, Lin A 1976 Isolation of eukaryotic ribosomal proteins. J Biol Chem 251:7940-7946
31. Witte S, Neumann F, Krawinkel U, Przybylski M 1996 Mass spectrometric identification of leucine zipper-like homodimer complexes of the autoantigen L7. J Biol Chem 271:18171-18175
32. von Mikecz AH, Hemmerich PH, Peter HH, Krawinkel U 1995 Autoantigenic epitopes on eukaryotic L7. Clin Exp Immunol 100:205-213
33. Neumann F, Hemmerich P, von Mikecz A, Peter HH, Krawinkel U 1995 Human ribosomal protein L7 inhibits cell-free translation in reticulocyte lysates and affects the expression of nuclear proteins upon stable transfection into Jurkat T-lymphoma cells. Nucleic Acids Res 23:195-202
34. von Mikecz A, Hemmerich P, Peter HH, Krawinkel U 1994 Characterization of eukaryotic protein L7 as a novel autoantigen which frequently elicits an immune response in patients suffering from systemic autoimmune disease. Immunobiology 192:137-54
35. Hemmerich P, von Mikecz A, Neumann F, Sozeri O, Wolff-Vorbeck G, Zoebelein R, Krawinkel U 1993 Structural and functional properties of ribosomal protein L7 from humans and rodents. Nucleic Acids Res 21:223-31
36. Mizuta K, Hashimoto T, Otaka E 1992 Yeast ribosomal proteins: XIII. Saccharomyces cerevisiae YL8A gene, interrupted with two introns, encodes a homolog of mammalian L7. Nucleic Acids Res 20:1011-1016
37. Misrahi M, Atger M, d'Auriol L, Loosfelt H, Meriel C, Fridlansky F, Guiochon-Mantel A, Galibert F, Milgrom E 1987 Complete amino acid sequence of the human progesterone receptor deduced from cloned DNA. Biochem Biophys Res Commun 143:740-748
38. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
39. O'Shea EK, Klemm JD, Kim PS, Alber T 1991 X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science 254:539-544
40. Turner R, Tjian R 1989 Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science 243:1689-1694
41. Bocquel M, Ji J, Ylikomi T, Benhamou B, Vergezac A, Chambon P, Gronemeyer H 1993 Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45:205-215
42. Klein-Hitpass L, Cato ACB, Henderson D, Ryffel GV 1991 Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19:1227-1234
43. Tung L, Mohamed KM, Hoeffler JP, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements, and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
44. Umesono K, Evans RM 1989 Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57:1139-1146
45. Danielsen M, Hinck L, Ringold GM 1989 Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor. Cell 57:1131-1138
46. Ptashne M 1988 How eukaryotic transcriptional activators work. Nature 335:683-689
47. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB 1992 Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89:3050-3054
48. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxyterminal tail of the human progesterone receptor. Cell 69:703-713
49. Allan GF, Leng XH, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520
50. Allan GF, Tsai SY, Tsai M-J, O'Malley BW 1992 Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. Proc Natl Acad Sci USA 89:11750-11754
51. Thomas M, Monet J-D 1992 Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75:865-870
52. Clarke CL, Sutherland RL 1990 Progestin regulation of cellular proliferation. Endocr Rev 11:266-302
53. Curtis RE, Boice J, JD, Shriner DA, Hankey BF, Fraumeni J, JF 1996 Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:832
54. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N 1995 Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies. J Natl Cancer Inst 87:645-651
55. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S 1994 Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318-1321
56. Epstein S, Newcomb PA, Jordan VC, Corbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
57. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R 1993 MCF-7/LCC2: a 4-hydroxy-tamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICH 82780. Cancer Res 53:3229-3232
58. Lykkesfeldt AE, Sorensen EK 1992 Effect of estrogen and anti-oestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31:131-138
59. R-I. Cancer Res 54:1587-1595
60. Adler S, Waterman ML, He X, Rosenfeld MG 1988 Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell 52:685-695
61. Yang NN, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222-1225
62. Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456
63. Norris JD, Fan D, Wagner BL, McDonnell DP 1996 Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endocrinol 10:1605-1616
64. Vojtek AB, Hollenberg SM, Cooper JA 1993 Mammalian Ras interacts directly with the serine/threonine Kinase Raf. Cell 74:205-214
65. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB 1994 A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8:1347-1360
66. Gietz RD, Schiestl RH 1989 Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier. Yeast 7:253-263
67. Schiestl RH, Gietz RD 1989 High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr Genet 16:339-346
68. Smith DB 1993 Purification of glutathione-S-transferase fusion proteins. Methods Mol Cell Biol 4:220-229
69. Frangioni JV, Neel BG 1993 Solubilization and purification of enzymatically active glutathione-S-transferase (pGEX) fusion proteins. Anal Biochem 210:179-187
70. Hope IA, Struhl K 1986 Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast. Cell 46:885-894
71. Hope IA, Struhl K 1985 GCN4 protein synthesized in vitro, binds HIS3 regulatory sequences: Implications for general control of amino acid biosynthetic genes in yeast. Cell 43:177-188